Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional)
This NIH R01 funds preclinical and patient-based research into how incretin mimetics (such as GLP-1 agents) affect cancer risk. Eligible applicants include universities, research institutions, trib…
- Deadline
- Jan 7, 2027
- Posted
- Nov 18, 2024
- Award amount
- Amount not specified
Don’t miss this deadline
We’ll email you before Jan 7, 2027 so you have time to apply.
In plain English
This NIH R01 funds preclinical and patient-based research into how incretin mimetics (such as GLP-1 agents) affect cancer risk. Eligible applicants include universities, research institutions, tribal and community organizations, and foreign organizations; a clinical trial is optional. It requires established research capacity in this area. No specific award amount is stated.
AI-generated summary to help you decide quickly — verify the official eligibility rules before applying.
Who can apply
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
About this grant
The goal of the proposed funding announcement is twofold, to promote preclinical and patient based studies examining the mechanism(s) through which incretin mimetics (including agonists or antagonists of GLP-1, GIP-1, or dual GLP-1/GIP-1 agents) impact cancer risk, and to draw talented scientists who understand the dynamic changes caused by these agents to investigate the mechanisms of how these agents influence cancer risk rather than shorter term outcomes such as weight loss and diabetes. The data thus far suggests that these agents may increase the risk of some, while decreasing the risk of other obesity related cancers.
Let AI draft your application
Your first draft is free: a narrative and budget outline tailored to this grant, emailed to you. Drafts are written in a nightly batch, so it arrives by email later — not instantly on this page.
Application Kit — $49 one-time
Winner intelligence + a first-draft narrative grounded in applications that actually won. One payment, no subscription.
Get the Application Kit →Related grants
Other open grants funding Education and Health — soonest deadline first.
Assay development and screening for discovery of chemical probes, drugs or immunomodulators (R01 Clinical Trial Not Allowed)
National Institutes of Health · Amount varies · Due in 17 days
Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01 Clinical Trial Not Allowed)
National Institutes of Health · Up to $499K · Due in 17 days
Substance Use/Substance Use Disorder Dissertation Research Award (R36 Clinical Trials Not Allowed)
National Institutes of Health · Amount varies · Due in 17 days
Specialized Programs of Research Excellence (SPOREs) in Human Cancers for Years 2024, 2025, and 2026 (P50 Clinical Trial Required)
National Institutes of Health · Amount varies · Due Sep 25, 2026
National Cancer Institute Youth Enjoy Science Research Education Program (R25 Clinical Trial Not Allowed)
National Institutes of Health · Up to $400K · Due Sep 28, 2026
BRAIN Initiative: Next-Generation Devices for Recording and Modulation in the Human Central Nervous System (UG3/UH3 Clinical Trial Optional)
National Institutes of Health · Amount varies · Due Sep 28, 2026
Also listed under National Institutes of Health, Education Grants and Health Grants.
Source: public records via Grants.gov. UseGrants is an independent aggregator, not affiliated with any funding agency. Always confirm details on the official listing before applying.